WorkBoat Header Background Image

WorkBoat+ Membership – Free to Join

Now Available: The U.S. Dredge Report 2025 — download today for expert dredging market insights and data → Click Here

Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xenon Pharmaceuticals Inc. - Common Shares (NQ:XENE)

55.53 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 26
Open 55.53
Bid (Size) 52.50 (100)
Ask (Size) 60.25 (100)
Prev. Close 55.53
Today's Range 55.53 - 55.53
52wk Range 26.74 - 63.95
Shares Outstanding 63,562,303
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough ↗
This biotech specializes in therapies for neurological disorders, advancing a diverse pipeline through late-stage trials and collaborations. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Battery Storage Stock Up 50% in a Year Draws New $110M Investment. Here's What You Should Know ↗
This energy storage firm develops battery solutions for utility and commercial clients, targeting grid-scale renewable energy markets. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
+24.8%
+24.8%
1 Month
+24.0%
+24.0%
3 Month
+23.8%
+23.8%
6 Month
+52.1%
+52.1%
1 Year
+59.7%
+59.7%

More News

Read More
News headline image
Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings ↗
Via The Motley Fool
Topics Regulatory Compliance
XENON PHARMACEUTICALS INC (NASDAQ:XENE) Reports Q4 and Full-Year 2025 Results, Focus Remains on Upcoming Phase 3 Data for Azetukalner ↗
Via Chartmill
News headline image
Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
The Azetukalner Breakthrough: A Deep Dive into Xenon Pharmaceuticals (XENE)
Via Finterra
Topics ETFs Intellectual Property
News headline image
Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
The Potassium Channel Breakthrough: A Deep-Dive on Xenon Pharmaceuticals (XENE)
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
News headline image
XENE Stock Rallies 50% On Epilepsy Trial Data, But One Analyst Thinks Rival Biohaven Still Has ‘Room To Differentiate’ ↗
Via Stocktwits
News headline image
Xenon Pharmaceuticals Announces Proposed Public Offering
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Top stock movements in today's session. ↗
Via Chartmill
Monday's session: top gainers and losers ↗
Via Chartmill
Gapping stocks in Monday's session ↗
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗
Via The Motley Fool
News headline image
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million ↗
Via The Motley Fool
Topics Regulatory Compliance

Frequently Asked Questions

Is Xenon Pharmaceuticals Inc. - Common Shares publicly traded?
Yes, Xenon Pharmaceuticals Inc. - Common Shares is publicly traded.
What exchange does Xenon Pharmaceuticals Inc. - Common Shares trade on?
Xenon Pharmaceuticals Inc. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Xenon Pharmaceuticals Inc. - Common Shares?
The ticker symbol for Xenon Pharmaceuticals Inc. - Common Shares is XENE on the Nasdaq Stock Market
What is the current price of Xenon Pharmaceuticals Inc. - Common Shares?
The current price of Xenon Pharmaceuticals Inc. - Common Shares is 55.53
When was Xenon Pharmaceuticals Inc. - Common Shares last traded?
The last trade of Xenon Pharmaceuticals Inc. - Common Shares was at 03/26/26 04:00 PM ET
What is the market capitalization of Xenon Pharmaceuticals Inc. - Common Shares?
The market capitalization of Xenon Pharmaceuticals Inc. - Common Shares is 3.53B
How many shares of Xenon Pharmaceuticals Inc. - Common Shares are outstanding?
Xenon Pharmaceuticals Inc. - Common Shares has 4B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Privacy Policy DSAR Requests Terms of Use Locations Events, Products & Services
© 2026 Diversified Communications. All rights reserved.